Comparison Study of Neoadjuvant Paclitaxel Plus Carboplatin/Epirubicin Treatment in Triple-negative Breast Cancer

Inclusion Criteria: * Women aged from 18 to 70 years; * WHO Performance status (ECOG) of 0 or 1 * Core biopsy histologically proven Ⅱa-Ⅲc phase breast cancer (regardless of the type); * Immunohistochemisty（IHC）：ER-，PR-，CerB2-；Triple negative （ER-PR-Her-2-） Hormone receptor negativity is defined as ER\<10%, PR\<10% (IHC), HER2 negativity is defined as IHC 0-1+, or \[IHC 2+ and FISH or CISH negative\]； * Adequate hematological function (neutrophil count ³ 2x109/l, platelet count ³ 100x 109/l, Hemoglobin \> 9 g/dl); * Adequate hepatic function: ASAT and ALAT £ 1.5 ULN alkaline phosphatases £ 2.5 ULN,total bilirubin £ 1,5 ULN; * Adequate renal function: serum creatinine £ 1.5 ULN; * Adequate cardiac function, LEVF value \> 50% by Muga scan or echocardiography，and electrocardiogram doe not show specific abnormality； * Patients accepting contraception intake during the overall length of treatment if of childbearing potential; * Signed written informed consent. Exclusion Criteria: * Any tumor ³ T4a (UICC1987) (cutaneous invasion, deep adherence, inflammatory breast cancer); * ER+ or PR+ or Her-2 overexpression * Any chemotherapy, hormonal therapy or radiotherapy before * Previous cancer in the preceding 10 years; * Patients already included in another therapeutic trial involving an experimental drug; * Patients with other concurrent severe and/or uncontrolled medical disease or infection which could compromise participation in the study; * LEVF \< 50% (MUGA scan or echocardiography); * Clinically significant cardiovascular disease (e.g. unstable angina, congestive heart failure, uncontrolled hypertension (\>150/90), myocardial infarction or cerebral vascular accidents) within 6 months prior to chemotherapy; * Known prior severe hypersensitivity reactions to agents that will be received; * Women who are pregnant or breastfeeding. Adequate birth control measures should be taken during study treatment phase; * Women with a positive pregnancy test en enrollment or prior to study drug administration; * Patients with any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial; * Individual deprived of liberty or placed under the authority of a tutor.